secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profusa, Inc. (PFSA)
CIK:        0001859807
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001213900-25-073072
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profusa strategy update: $100M ELOC secured, EU launch Q1 2026, FDA submission mid-2026
--------------------------------------------------------------------------------

- Became public on Nasdaq July 14, 2025; strategy focused on five pillars including revenue growth and AI infrastructure.
- First distributor partner in Spain for Lumee tissue oxygen platform; EU commercial launch targeted Q1 2026.
- U.S. FDA submission planned mid-2026 with U.S. commercialization anticipated mid-2027 for oxygen monitoring.
- Continuous glucose monitoring: human validation data expected in peer-reviewed journal; pivotal studies later 2026.
- Secured $100M ELOC facility and implementing digital investment treasury plan to support growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859807/000121390025073072/0001213900-25-073072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859807/000121390025073072/ea0252144-8k_profusa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer